SCHEMBL3584065

SCHEMBL3584065

Nc1c[nH]nc1-c1cnccn1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSP90AA1 P07900 1/20 0.39
NISCH Q9Y2I1 1/20 0.37
RECQL P46063 2/20 0.35
HTT P42858 1/20 0.35
PIM1 P11309 4/20 0.35
CHEK1 O14757 1/20 0.33
PIK3CD O00329 1/20 0.33
PIK3CA P42336 1/20 0.33
PIK3CB P42338 1/20 0.33
PI4KA P42356 1/20 0.33
PIK3CG P48736 1/20 0.33
PI4KB Q9UBF8 1/20 0.33
CYP2D6 P10635 1/20 0.33
CYP19A1 P11511 1/20 0.33
CYP2C9 P11712 1/20 0.33
CYP2C19 P33261 1/20 0.33
METAP2 P50579 1/20 0.33
KDM4E B2RXH2 3/20 0.32
CYP3A4 P08684 1/20 0.32
GAA P10253 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3579139 0.74 KDM4E (0.46) HSP90AA1HTTPIM1METAP2KDM4E
SCHEMBL4441206 0.73 PIM1 (0.41) PIM1PIK3CDPIK3CAPIK3CBPI4KA
SCHEMBL29132841 0.73 NISCH (0.37) NISCHPIM1CYP2C9METAP2KDM4E
SCHEMBL30703605 0.73 NISCH (0.37) NISCHPIM1CYP2C9METAP2KDM4E
SCHEMBL28540095 0.70 NISCH (0.45) HSP90AA1NISCHRECQLHTTPIM1
SCHEMBL28143115 0.70 HSP90AA1 (0.46) HSP90AA1NISCHRECQLHTTPIM1
SCHEMBL30958344 0.69 ADORA2A (0.43) HSP90AA1NISCHRECQLHTTPIM1
SCHEMBL18292300 0.69 PIM1 (0.43) NISCHPIM1CYP2D6CYP19A1CYP2C9
SCHEMBL2121118 0.69 AXL (0.49) HTTPIM1CYP2D6CYP2C9CYP2C19
SCHEMBL13314752 0.68 KMT2A (0.41) KDM4EGAAALDH1A1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100160324-A1 PYRAZOLE DERIVATIVES AS THAT MODULATE THE ACTIVITY OF CDK, GSK AND AURORA KINASES ASTEX THERAPEUTICS LIMITED (GB) 2010-06-24 US disclosed
US-20100160324-A1 PYRAZOLE DERIVATIVES AS THAT MODULATE THE ACTIVITY OF CDK, GSK AND AURORA KINASES ASTEX THERAPEUTICS LIMITED (GB) 2010-06-24 US disclosed
US-20100160324-A1 PYRAZOLE DERIVATIVES AS THAT MODULATE THE ACTIVITY OF CDK, GSK AND AURORA KINASES ASTEX THERAPEUTICS LIMITED (GB) 2010-06-24 US disclosed
EP-1836188-A1 PYRAZOLE DERIVATIVES AS THAT MODULATE THE ACTIVITY OF CDK, GSK AND AURORA KINASES Astex Therapeutics Limited (GB) 2007-09-26 EP disclosed
WO-2006070198-A1 PYRAZOLE DERIVATIVES AS THAT MODULATE THE ACTIVITY OF CDK, GSK AND AURORA KINASES ASTEX THERAPEUTICS LIMITED (GB) 2006-07-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100160324-A1 PYRAZOLE DERIVATIVES AS THAT MODULATE THE ACTIVITY OF CDK, GSK AND AURORA KINASES CDK1, CDK3, CDK13 HSP90AA1 4023/4885NISCH 4584/4885RECQL 1025/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.